Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
F. Dayyani
Observed names:
F Dayyani,
Farshid Dayyani
Institutions:
University of California, Irvine,
University of California, Irvine Medical Center,
UC Irvine Chao Family Comprehensive Cancer Center
Observed institutions:
University of California, Irvine,
University of California, Irvine Medical Center,
UC Irvine Chao Family Comprehensive Cancer Center
ORCID:
0000-0002-4970-5189
Observed ORCID:
0000-0002-4970-5189
OpenAlex ID:
A5021790712
79P Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
2022
·
A. Vogel
, S.L. Chan
, et al.
·
Annals of Oncology
·
9
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy
2026
·
Sakti Chakrabarti
, Stacey A. Cohen
, et al.
·
Cancers
·
5
PDF
86P Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
2022
·
A.R. He
, J.W. Valle
, et al.
·
Annals of Oncology
·
4
O-1 Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study
2022
·
A. He
, J. Valle
, et al.
·
Annals of Oncology
·
3
939P Phase I, dose-escalation study evaluating safety & efficacy of trastuzumab deruxtecan (T-DXd) in combination with ATR inhibitor (AZD6738, ceralasertib) in advanced solid tumors with HER2 expression (DASH)
2025
·
K. Raghav
, Y. Yuan
, et al.
·
Annals of Oncology
·
2
PDF
319MO Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer
2022
·
S.A. Cohen
, P.M. Kasi
, et al.
·
Annals of Oncology
·
2
323P Early safety and efficacy from the phase IIIb TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC)
2025
·
D-Y. Oh
, M. Ikeda
, et al.
·
Annals of Oncology
·
1
PDF
950P Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
2024
·
M. Kudo
, R. Lencioni
, et al.
·
Annals of Oncology
·
1
PDF
166P Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
2024
·
S.L. Chan
, T. Decaens
, et al.
·
Annals of Oncology
·
1
PDF
289P Treatment outcomes in previously treated patients with advanced/metastatic HER2+ biliary tract cancer: A systematic review
2024
·
S. Paisley
, S. Bowditch
, et al.
·
Annals of Oncology
·
1
PDF
2945P Expanded safety and efficacy of givastomig, a claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in 1L metastatic gastroesophageal carcinoma (mGEC)
2026
·
S.J. Klempner
, F. Dayyani
, et al.
·
Annals of Oncology
Safety outcomes with tremelimumab (T) rechallenge in the Phase 3 HIMALAYA study of T plus durvalumab (D) in unresectable hepatocellular carcinoma
2026
·
P R Galle
, R K Kelley
, et al.
·
Zeitschrift für Gastroenterologie
Outcomes by prior locoregional therapy use from the phase 3 HIMALAYA study of tremelimumab+durvalumab in unresectable hepatocellular carcinoma
2026
·
T Ettrich
, B Sangro
, et al.
·
Zeitschrift für Gastroenterologie
350P Safety and efficacy of durvalumab plus gemcitabine (gem)-based chemotherapy (chemo) regimens in participants (pts) with advanced biliary tract cancer (aBTC): Primary results from the phase IIIb TOURMALINE study
2026
·
D-Y. Oh
, M. Ikeda
, et al.
·
Annals of Oncology
PDF
133O Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results
2024
·
D-Y. Oh
, M. Ikeda
, et al.
·
Annals of Oncology
PDF
199P Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
2024
·
M. Kudo
, R. Lencioni
, et al.
·
Annals of Oncology
Effect of Interval between Neoadjuvant Chemotherapy and Radiation Therapy on Metastasis Risk for Inoperable Non-Metastatic Pancreatic Adenocarcinoma
2023
·
S.N. Seyedin
, A. Fattah
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
Overall Survival after Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Patients
2022
·
J. Yeakel
, J.V. Kuo
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
Show more works
View as search
Works count:
18
Citation count:
28
H-index:
3
I10-index:
Year
Topic
Type